Recent study shows significant reduction in cough frequency

A recent pooled study by Smith JA et al. (2021) investigated cough frequency in chronic cough patients treated with gefapixant. “In this pooled analysis, gefapixant 45 mg BID demonstrated significant reductions in 24-hour and awake cough frequency vs placebo, with no increase in serious AEs”.

[vital_featured_image]

The VitaloJAK™ was used to measure objective cough frequency in this study. Vitalograph’s expert team of cough analysts and the highly consistent performance of the VitaloJAK continue to provide industry-leading objective cough data across different disease areas.

Clinical Trials

Clinical Trial Services

Our clinical trial services are designed to add value to your specific study needs and to contribute to the operational design of your study. 

Data
Project
Clinical
Training
Software
eCOA
Support

Contact Us